Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) is in advanced-stage evaluation to acquire a niche contract research organization (CRO) with operations in over 20 countries, poised to add $20 million+ in annual revenue and support double-digit growth. This potential acquisition aligns with Tevogen's strategy to diversify and expand its healthcare services…